{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:44:39Z","timestamp":1770813879099,"version":"3.50.1"},"reference-count":46,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Context.<\/jats:italic>\n                    \u2014Fondaparinux, a factor Xa inhibitor, is approved for thromboprophylaxis after orthopedic surgery and for treatment of venous thromboembolism. It may also be efficacious, safe, and cost-effective for other patients; thus, more widespread use of fondaparinux is likely. The effect of fondaparinux on coagulation testing needs to be thoroughly examined.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Objective.<\/jats:italic>\n                    \u2014To report the effects of fondaparinux on coagulation tests (prothrombin time, activated partial thromboplastin time, fibrinogen, antithrombin, factor VIII, thrombin time, anti\u2013factor Xa) across diverse methodologies.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Design.<\/jats:italic>\n                    \u2014Samples with different concentrations of fondaparinux (0, 0.4, 0.8, and 2.0 \u03bcg\/mL) were sent to laboratories participating in the College of American Pathologists Comprehensive Coagulation proficiency survey (N = 898). Laboratory-specific methods were used to assay coagulation parameters.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results.<\/jats:italic>\n                    \u2014Prophylactic or therapeutic fondaparinux prolonged the prothrombin time by approximately 1 second and the activated partial thromboplastin time by 4 to 5 seconds, and reduced factor VIII from 119% to 107% and 102%, respectively. Supratherapeutic fondaparinux reduced factor VIII to 85%. The activated partial thromboplastin time was prolonged in 19%, 29%, and 52% of laboratories with prophylactic, therapeutic, and supratherapeutic fondaparinux levels, respectively. Fibrinogen, antithrombin, and thrombin time assays did not show clinically significant changes. When measuring fondaparinux concentration using an anti\u2013factor Xa assay, the most accurate results were obtained when fondaparinux was used as the calibrator.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusions.<\/jats:italic>\n                    \u2014Fondaparinux, even in prophylactic doses, slightly prolongs the prothrombin time and activated partial thromboplastin time and can interfere with factor VIII assays, but it has no clinically relevant effect on fibrinogen, antithrombin, or thrombin time. A fondaparinux standard curve should be used for reporting fondaparinux levels using an anti\u2013factor Xa assay.\n                  <\/jats:p>","DOI":"10.5858\/2006-130-1605-eofoca","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T09:33:16Z","timestamp":1613035996000},"page":"1605-1611","source":"Crossref","is-referenced-by-count":36,"title":["Effect of Fondaparinux on Coagulation Assays: Results of College of American Pathologists Proficiency Testing"],"prefix":"10.5858","volume":"130","author":[{"given":"Agata","family":"Smogorzewska","sequence":"first","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine (Drs Smogorzewska and Van Cott), Harvard Medical School, Massachusetts General Hospital, Boston; Eli Lilly & Co, Indianapolis, Ind (Dr Brandt); Department of Laboratory Medicine, Harborview Medical Center, University of Washington, Seattle (Dr Chandler); Department of Pathology, University of Kansas Medical Center, Kansas City (Dr Cunningham); Department of Pathology, Maine Medical Center, Portland (Dr Hayes); Department of Pathology..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Brandt","sequence":"additional","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine (Drs Smogorzewska and Van Cott), Harvard Medical School, Massachusetts General Hospital, Boston; Eli Lilly & Co, Indianapolis, Ind (Dr Brandt); Department of Laboratory Medicine, Harborview Medical Center, University of Washington, Seattle (Dr Chandler); Department of Pathology, University of Kansas Medical Center, Kansas City (Dr Cunningham); Department of Pathology, Maine Medical Center, Portland (Dr Hayes); Department of Pathology..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne L.","family":"Chandler","sequence":"additional","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine (Drs Smogorzewska and Van Cott), Harvard Medical School, Massachusetts General Hospital, Boston; Eli Lilly & Co, Indianapolis, Ind (Dr Brandt); Department of Laboratory Medicine, Harborview Medical Center, University of Washington, Seattle (Dr Chandler); Department of Pathology, University of Kansas Medical Center, Kansas City (Dr Cunningham); Department of Pathology, Maine Medical Center, Portland (Dr Hayes); Department of Pathology..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark T.","family":"Cunningham","sequence":"additional","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine (Drs Smogorzewska and Van Cott), Harvard Medical School, Massachusetts General Hospital, Boston; Eli Lilly & Co, Indianapolis, Ind (Dr Brandt); Department of Laboratory Medicine, Harborview Medical Center, University of Washington, Seattle (Dr Chandler); Department of Pathology, University of Kansas Medical Center, Kansas City (Dr Cunningham); Department of Pathology, Maine Medical Center, Portland (Dr Hayes); Department of Pathology..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy E.","family":"Hayes","sequence":"additional","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine (Drs Smogorzewska and Van Cott), Harvard Medical School, Massachusetts General Hospital, Boston; Eli Lilly & Co, Indianapolis, Ind (Dr Brandt); Department of Laboratory Medicine, Harborview Medical Center, University of Washington, Seattle (Dr Chandler); Department of Pathology, University of Kansas Medical Center, Kansas City (Dr Cunningham); Department of Pathology, Maine Medical Center, Portland (Dr Hayes); Department of Pathology..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Olson","sequence":"additional","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine (Drs Smogorzewska and Van Cott), Harvard Medical School, Massachusetts General Hospital, Boston; Eli Lilly & Co, Indianapolis, Ind (Dr Brandt); Department of Laboratory Medicine, Harborview Medical Center, University of Washington, Seattle (Dr Chandler); Department of Pathology, University of Kansas Medical Center, Kansas City (Dr Cunningham); Department of Pathology, Maine Medical Center, Portland (Dr Hayes); Department of Pathology..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kandice","family":"Kottke-Marchant","sequence":"additional","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine (Drs Smogorzewska and Van Cott), Harvard Medical School, Massachusetts General Hospital, Boston; Eli Lilly & Co, Indianapolis, Ind (Dr Brandt); Department of Laboratory Medicine, Harborview Medical Center, University of Washington, Seattle (Dr Chandler); Department of Pathology, University of Kansas Medical Center, Kansas City (Dr Cunningham); Department of Pathology, Maine Medical Center, Portland (Dr Hayes); Department of Pathology..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Van Cott","sequence":"additional","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine (Drs Smogorzewska and Van Cott), Harvard Medical School, Massachusetts General Hospital, Boston; Eli Lilly & Co, Indianapolis, Ind (Dr Brandt); Department of Laboratory Medicine, Harborview Medical Center, University of Washington, Seattle (Dr Chandler); Department of Pathology, University of Kansas Medical Center, Kansas City (Dr Cunningham); Department of Pathology, Maine Medical Center, Portland (Dr Hayes); Department of Pathology..."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","reference":[{"key":"i1543-2165-130-11-1605-b1","series-title":"N Engl J Med","first-page":"1298","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.","volume":"345","author":"Eriksson, B. I.","year":"2001","unstructured":"Eriksson, B. I., K. A.Bauer, M. R.Lassen, and A. G.Turpie. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.N Engl J Med2001. 345:1298\u20131304."},{"key":"i1543-2165-130-11-1605-b2","series-title":"N Engl J Med","first-page":"1305","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.","volume":"345","author":"Bauer, K. A.","year":"2001","unstructured":"Bauer, K. A., B. I.Eriksson, M. R.Lassen, and A. G.Turpie. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.N Engl J Med2001. 345:1305\u20131310."},{"key":"i1543-2165-130-11-1605-b3","series-title":"Lancet","first-page":"1715","article-title":"Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.","volume":"359","author":"Lassen, M. R.","year":"2002","unstructured":"Lassen, M. R., K. A.Bauer, B. I.Eriksson, and A. G.Turpie. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.Lancet2002. 359:1715\u20131720."},{"key":"i1543-2165-130-11-1605-b4","series-title":"Lancet","first-page":"1721","article-title":"Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.","volume":"359","author":"Turpie, A. G.","year":"2002","unstructured":"Turpie, A. G., K. A.Bauer, B. I.Eriksson, and M. R.Lassen. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.Lancet2002. 359:1721\u20131726."},{"key":"i1543-2165-130-11-1605-b5","series-title":"Arch Intern Med","first-page":"1337","article-title":"Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.","volume":"163","author":"Eriksson, B. I.","year":"2003","unstructured":"Eriksson, B. I. and M. R.Lassen. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.Arch Intern Med2003. 163:1337\u20131342."},{"key":"i1543-2165-130-11-1605-b6","article-title":"A randomized double-blind study to compare the efficacy and safety of postoperative fondaparinux and preoperative dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS Study.","author":"Agnelli, G.","unstructured":"Agnelli, G., D.Berqvist, A.Cohen, A.Gallus, and M.Gent. A randomized double-blind study to compare the efficacy and safety of postoperative fondaparinux and preoperative dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS Study.Blood. 2003;102."},{"key":"i1543-2165-130-11-1605-b7","article-title":"Fondaparinux for the prevention of VTE in acutely ill medical patients.","author":"Cohen, A.","unstructured":"Cohen, A., B. L.Davidson, and A.Gallus. et al. Fondaparinux for the prevention of VTE in acutely ill medical patients.Blood. 2003;102."},{"key":"i1543-2165-130-11-1605-b8","series-title":"N Engl J Med","first-page":"1695","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.","volume":"349","author":"Buller, H. R.","year":"2003","unstructured":"Buller, H. R., B. L.Davidson, and H.Decousus. et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.N Engl J Med2003. 349:1695\u20131702."},{"key":"i1543-2165-130-11-1605-b9","series-title":"Ann Intern Med","first-page":"867","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.","volume":"140","author":"Buller, H. R.","year":"2004","unstructured":"Buller, H. R., B. L.Davidson, and H.Decousus. et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.Ann Intern Med2004. 140:867\u2013873."},{"key":"i1543-2165-130-11-1605-b10","series-title":"Eur Heart J","first-page":"1716","article-title":"A synthetic factor-Xa inhibitor (ORG31540\/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: the PENTALYSE study.","volume":"22","author":"Coussement, P. K.","year":"2001","unstructured":"Coussement, P. K., J. P.Bassand, and C.Convens. et al. A synthetic factor-Xa inhibitor (ORG31540\/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: the PENTALYSE study.Eur Heart J2001. 22:1716\u20131724."},{"key":"i1543-2165-130-11-1605-b11","series-title":"J Am Coll Cardiol","first-page":"2183","article-title":"A dose-finding study of fondaparinux in patients with non\u2013ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.","volume":"43","author":"Simoons, M. L.","year":"2004","unstructured":"Simoons, M. L., I. W.Bobbink, and J.Boland. et al. A dose-finding study of fondaparinux in patients with non\u2013ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.J Am Coll Cardiol2004. 43:2183\u20132190."},{"key":"i1543-2165-130-11-1605-b12","series-title":"Eur J Clin Invest","first-page":"27","article-title":"Fondaparinux: an update on new study results.","volume":"35","author":"Bauersachs, R. M.","year":"2005","unstructured":"Bauersachs, R. M.\n          \n          Fondaparinux: an update on new study results.\n          Eur J Clin Invest\n          2005. 35:(suppl 1). 27\u201332."},{"key":"i1543-2165-130-11-1605-b13","series-title":"Clin Appl Thromb Hemost","first-page":"259","article-title":"Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies.","volume":"5","author":"Ahmad, S.","year":"1999","unstructured":"Ahmad, S., W. P.Jeske, and J. M.Walenga. et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies.Clin Appl Thromb Hemost1999. 5:259\u2013266."},{"key":"i1543-2165-130-11-1605-b14","series-title":"Blood Coagul Fibrinolysis","first-page":"114","article-title":"Absence of cross-reactivity of SR90107A\/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia.","volume":"8","author":"Amiral, J.","year":"1997","unstructured":"Amiral, J., J. C.Lormeau, and A.Marfaing-Koka. et al. Absence of cross-reactivity of SR90107A\/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia.Blood Coagul Fibrinolysis1997. 8:114\u2013117."},{"key":"i1543-2165-130-11-1605-b15","series-title":"Thromb Haemost","first-page":"1384","article-title":"Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia.","volume":"74","author":"Elalamy, I.","year":"1995","unstructured":"Elalamy, I., C.Lecrubier, and F.Potevin. et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia.Thromb Haemost1995. 74:1384\u20131385."},{"key":"i1543-2165-130-11-1605-b16","series-title":"Thromb Haemost","first-page":"886","article-title":"Characterization of the structural requirements for a carbohydrate-based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia.","volume":"74","author":"Greinacher, A.","year":"1995","unstructured":"Greinacher, A., S.Alban, V.Dummel, G.Franz, and C.Mueller-Eckhardt. Characterization of the structural requirements for a carbohydrate-based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia.Thromb Haemost1995. 74:886\u2013892."},{"key":"i1543-2165-130-11-1605-b17","series-title":"Blood","first-page":"139","article-title":"Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin.","volume":"105","author":"Savi, P.","year":"2005","unstructured":"Savi, P., B. H.Chong, and A.Greinacher. et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin.Blood2005. 105:139\u2013144."},{"key":"i1543-2165-130-11-1605-b18","series-title":"Blood","first-page":"3791","article-title":"Anti\u2013platelet factor 4\/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.","volume":"106","author":"Warkentin, T. E.","year":"2005","unstructured":"Warkentin, T. E., R. J.Cook, and V. J.Marder. et al. Anti\u2013platelet factor 4\/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.Blood2005. 106:3791\u20133796."},{"key":"i1543-2165-130-11-1605-b19","series-title":"Haematologica","first-page":"1017","article-title":"Treatment of heparin-induced thrombocytopenia with fondaparinux.","volume":"89","author":"Harenberg, J.","year":"2004","unstructured":"Harenberg, J., I.Jorg, and T.Fenyvesi. Treatment of heparin-induced thrombocytopenia with fondaparinux.Haematologica2004. 89:1017\u20131018."},{"key":"i1543-2165-130-11-1605-b20","series-title":"Thromb Haemost","first-page":"1468","article-title":"Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107\/Org31540) with high affinity to antithrombin III in man.","volume":"74","author":"Boneu, B.","year":"1995","unstructured":"Boneu, B., J.Necciari, and R.Cariou. et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107\/Org31540) with high affinity to antithrombin III in man.Thromb Haemost1995. 74:1468\u20131473."},{"key":"i1543-2165-130-11-1605-b21","series-title":"Arch Pathol Lab Med","first-page":"1142","article-title":"Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing.","volume":"128","author":"Gosselin, R. C.","year":"2004","unstructured":"Gosselin, R. C., J. H.King, K. A.Janatpur, W. H.Dager, E. C.Larkin, and J. T.Owings. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing.Arch Pathol Lab Med2004. 128:1142\u20131145."},{"issue":"suppl 2","key":"i1543-2165-130-11-1605-b22","series-title":"Clin Pharmacokinet","first-page":"1","article-title":"The pharmacokinetics of fondaparinux sodium in healthy volunteers.","volume":"41","author":"Donat, F.","year":"2002","unstructured":"Donat, F., J. P.Duret, and A.Santoni. et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers.Clin Pharmacokinet2002. 41suppl 2:1\u20139."},{"key":"i1543-2165-130-11-1605-b23","series-title":"Blood","first-page":"3631","article-title":"A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism.","volume":"104","author":"Tripodi, A.","year":"2004","unstructured":"Tripodi, A., V.Chantarangkul, I.Martinelli, P.Bucciarelli, and P. M.Mannucci. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism.Blood2004. 104:3631\u20133634."},{"key":"i1543-2165-130-11-1605-b1","series-title":"N Engl J Med","first-page":"1298","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.","volume":"345","author":"Eriksson, B. I.","year":"2001","unstructured":"Eriksson, B. I., K. A.Bauer, M. R.Lassen, and A. G.Turpie. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.N Engl J Med2001. 345:1298\u20131304."},{"key":"i1543-2165-130-11-1605-b2","series-title":"N Engl J Med","first-page":"1305","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.","volume":"345","author":"Bauer, K. A.","year":"2001","unstructured":"Bauer, K. A., B. I.Eriksson, M. R.Lassen, and A. G.Turpie. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.N Engl J Med2001. 345:1305\u20131310."},{"key":"i1543-2165-130-11-1605-b3","series-title":"Lancet","first-page":"1715","article-title":"Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.","volume":"359","author":"Lassen, M. R.","year":"2002","unstructured":"Lassen, M. R., K. A.Bauer, B. I.Eriksson, and A. G.Turpie. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.Lancet2002. 359:1715\u20131720."},{"key":"i1543-2165-130-11-1605-b4","series-title":"Lancet","first-page":"1721","article-title":"Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.","volume":"359","author":"Turpie, A. G.","year":"2002","unstructured":"Turpie, A. G., K. A.Bauer, B. I.Eriksson, and M. R.Lassen. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.Lancet2002. 359:1721\u20131726."},{"key":"i1543-2165-130-11-1605-b5","series-title":"Arch Intern Med","first-page":"1337","article-title":"Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.","volume":"163","author":"Eriksson, B. I.","year":"2003","unstructured":"Eriksson, B. I. and M. R.Lassen. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.Arch Intern Med2003. 163:1337\u20131342."},{"key":"i1543-2165-130-11-1605-b6","article-title":"A randomized double-blind study to compare the efficacy and safety of postoperative fondaparinux and preoperative dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS Study.","author":"Agnelli, G.","unstructured":"Agnelli, G., D.Berqvist, A.Cohen, A.Gallus, and M.Gent. A randomized double-blind study to compare the efficacy and safety of postoperative fondaparinux and preoperative dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS Study.Blood. 2003;102."},{"key":"i1543-2165-130-11-1605-b7","article-title":"Fondaparinux for the prevention of VTE in acutely ill medical patients.","author":"Cohen, A.","unstructured":"Cohen, A., B. L.Davidson, and A.Gallus. et al. Fondaparinux for the prevention of VTE in acutely ill medical patients.Blood. 2003;102."},{"key":"i1543-2165-130-11-1605-b8","series-title":"N Engl J Med","first-page":"1695","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.","volume":"349","author":"Buller, H. R.","year":"2003","unstructured":"Buller, H. R., B. L.Davidson, and H.Decousus. et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.N Engl J Med2003. 349:1695\u20131702."},{"key":"i1543-2165-130-11-1605-b9","series-title":"Ann Intern Med","first-page":"867","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.","volume":"140","author":"Buller, H. R.","year":"2004","unstructured":"Buller, H. R., B. L.Davidson, and H.Decousus. et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.Ann Intern Med2004. 140:867\u2013873."},{"key":"i1543-2165-130-11-1605-b10","series-title":"Eur Heart J","first-page":"1716","article-title":"A synthetic factor-Xa inhibitor (ORG31540\/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: the PENTALYSE study.","volume":"22","author":"Coussement, P. K.","year":"2001","unstructured":"Coussement, P. K., J. P.Bassand, and C.Convens. et al. A synthetic factor-Xa inhibitor (ORG31540\/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: the PENTALYSE study.Eur Heart J2001. 22:1716\u20131724."},{"key":"i1543-2165-130-11-1605-b11","series-title":"J Am Coll Cardiol","first-page":"2183","article-title":"A dose-finding study of fondaparinux in patients with non\u2013ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.","volume":"43","author":"Simoons, M. L.","year":"2004","unstructured":"Simoons, M. L., I. W.Bobbink, and J.Boland. et al. A dose-finding study of fondaparinux in patients with non\u2013ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.J Am Coll Cardiol2004. 43:2183\u20132190."},{"key":"i1543-2165-130-11-1605-b12","series-title":"Eur J Clin Invest","first-page":"27","article-title":"Fondaparinux: an update on new study results.","volume":"35","author":"Bauersachs, R. M.","year":"2005","unstructured":"Bauersachs, R. M.\n          \n          Fondaparinux: an update on new study results.\n          Eur J Clin Invest\n          2005. 35:(suppl 1). 27\u201332."},{"key":"i1543-2165-130-11-1605-b13","series-title":"Clin Appl Thromb Hemost","first-page":"259","article-title":"Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies.","volume":"5","author":"Ahmad, S.","year":"1999","unstructured":"Ahmad, S., W. P.Jeske, and J. M.Walenga. et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies.Clin Appl Thromb Hemost1999. 5:259\u2013266."},{"key":"i1543-2165-130-11-1605-b14","series-title":"Blood Coagul Fibrinolysis","first-page":"114","article-title":"Absence of cross-reactivity of SR90107A\/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia.","volume":"8","author":"Amiral, J.","year":"1997","unstructured":"Amiral, J., J. C.Lormeau, and A.Marfaing-Koka. et al. Absence of cross-reactivity of SR90107A\/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia.Blood Coagul Fibrinolysis1997. 8:114\u2013117."},{"key":"i1543-2165-130-11-1605-b15","series-title":"Thromb Haemost","first-page":"1384","article-title":"Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia.","volume":"74","author":"Elalamy, I.","year":"1995","unstructured":"Elalamy, I., C.Lecrubier, and F.Potevin. et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia.Thromb Haemost1995. 74:1384\u20131385."},{"key":"i1543-2165-130-11-1605-b16","series-title":"Thromb Haemost","first-page":"886","article-title":"Characterization of the structural requirements for a carbohydrate-based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia.","volume":"74","author":"Greinacher, A.","year":"1995","unstructured":"Greinacher, A., S.Alban, V.Dummel, G.Franz, and C.Mueller-Eckhardt. Characterization of the structural requirements for a carbohydrate-based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia.Thromb Haemost1995. 74:886\u2013892."},{"key":"i1543-2165-130-11-1605-b17","series-title":"Blood","first-page":"139","article-title":"Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin.","volume":"105","author":"Savi, P.","year":"2005","unstructured":"Savi, P., B. H.Chong, and A.Greinacher. et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin.Blood2005. 105:139\u2013144."},{"key":"i1543-2165-130-11-1605-b18","series-title":"Blood","first-page":"3791","article-title":"Anti\u2013platelet factor 4\/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.","volume":"106","author":"Warkentin, T. E.","year":"2005","unstructured":"Warkentin, T. E., R. J.Cook, and V. J.Marder. et al. Anti\u2013platelet factor 4\/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.Blood2005. 106:3791\u20133796."},{"key":"i1543-2165-130-11-1605-b19","series-title":"Haematologica","first-page":"1017","article-title":"Treatment of heparin-induced thrombocytopenia with fondaparinux.","volume":"89","author":"Harenberg, J.","year":"2004","unstructured":"Harenberg, J., I.Jorg, and T.Fenyvesi. Treatment of heparin-induced thrombocytopenia with fondaparinux.Haematologica2004. 89:1017\u20131018."},{"key":"i1543-2165-130-11-1605-b20","series-title":"Thromb Haemost","first-page":"1468","article-title":"Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107\/Org31540) with high affinity to antithrombin III in man.","volume":"74","author":"Boneu, B.","year":"1995","unstructured":"Boneu, B., J.Necciari, and R.Cariou. et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107\/Org31540) with high affinity to antithrombin III in man.Thromb Haemost1995. 74:1468\u20131473."},{"key":"i1543-2165-130-11-1605-b21","series-title":"Arch Pathol Lab Med","first-page":"1142","article-title":"Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing.","volume":"128","author":"Gosselin, R. C.","year":"2004","unstructured":"Gosselin, R. C., J. H.King, K. A.Janatpur, W. H.Dager, E. C.Larkin, and J. T.Owings. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing.Arch Pathol Lab Med2004. 128:1142\u20131145."},{"issue":"suppl 2","key":"i1543-2165-130-11-1605-b22","series-title":"Clin Pharmacokinet","first-page":"1","article-title":"The pharmacokinetics of fondaparinux sodium in healthy volunteers.","volume":"41","author":"Donat, F.","year":"2002","unstructured":"Donat, F., J. P.Duret, and A.Santoni. et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers.Clin Pharmacokinet2002. 41suppl 2:1\u20139."},{"key":"i1543-2165-130-11-1605-b23","series-title":"Blood","first-page":"3631","article-title":"A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism.","volume":"104","author":"Tripodi, A.","year":"2004","unstructured":"Tripodi, A., V.Chantarangkul, I.Martinelli, P.Bucciarelli, and P. M.Mannucci. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism.Blood2004. 104:3631\u20133634."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/130\/11\/article-p1605.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/130\/11\/1605\/2759577\/1543-2165(2006)130%255b1605_eofoca%255d2_0_co_2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/130\/11\/article-p1605.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/130\/11\/article-p1605.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:56:58Z","timestamp":1770771418000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/130\/11\/article-p1605.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":46,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.5858\/2006-130-1605-eofoca","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}